Zobrazeno 1 - 10
of 68
pro vyhledávání: '"Steven N. Wolff"'
Autor:
Mona N. Fouad, Marjorie J. Good, William J. Hicks, Robert L. Comis, Stephen S. Grubbs, Steven Joffe, Worta McCaskill-Stevens, Steven N. Wolff, Rebecca A. Enos, Afshin Dowlati, Michelle E. Duff, Ellen S. Richmond, Kevin P. Weinfurt, Michael A. Bookman, Patrick J. Loehrer, Robin T. Zon, Neal J. Meropol, Andrea Denicoff, Terrance L. Albrecht, Alan P. Lyss, Margo Michaels, Jean G. Ford, Lidia Schapira, Debra Wujcik, Derek Raghavan, David M. Dilts, Suanna S. Bruinooge, Peggy Devine
Publikováno v:
Journal of Oncology Practice. 9:267-276
Many challenges to clinical trial accrual exist, resulting in studies with inadequate enrollment and potentially delaying answers to important scientific and clinical questions.The National Cancer Institute (NCI) and the American Society of Clinical
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::3c4b7b2e3ca54a3aa05e5be92cfc3bda
https://doi.org/10.1200/jop.2013.001119
https://doi.org/10.1200/jop.2013.001119
Autor:
Debra Wujcik, Steven N. Wolff, Rebecca Selove, Maureen Sanderson, David Shen-Miller, Pamela C. Hull, Debra L. Friedman, Maya Foster
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::eb85c087f924323eef2b63f7ea7eec81
https://europepmc.org/articles/PMC5269536/
https://europepmc.org/articles/PMC5269536/
Autor:
Steven N. Wolff, Debra Wujcik
Publikováno v:
Journal of Health Care for the Poor and Underserved. 21:38-50
In 2000, using National Institutes of Health/National Cancer Institute (NIH/NCI) U54 funds, a clinical trials shared resource was established at Nashville General Hospital at Meharry to attract more African Americans to national cancer clinical trial
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::7c79450bc112f85bd0fd8de12986ffce
https://doi.org/10.1353/hpu.0.0251
https://doi.org/10.1353/hpu.0.0251
Autor:
John R. Wingard, Charles A. Linker, J. Jiao, Barbara E. Bierer, M. A. Petrarca, Joseph H. Antin, Gary J. Schiller, Herbert Kaizer, Trudy N. Small, Hillard M. Lazarus, Steven N. Wolff, Drew J. Winston, Mj J. Cowan, Mary C. Territo, S. A. Tonetta, Kenneth B. Miller, Winston G. Ho, F. B. Petersen
Publikováno v:
Bone Marrow Transplantation. 28:187-196
Intravenous immunoglobulin is approved for use in allogeneic bone marrow transplant recipients for prevention of graft-versus-host disease (GVHD) and infections, but the minimally effective dose has not been established. In this multicenter, randomiz
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::9ff6921227d5f051725204359f95fb23
https://doi.org/10.1038/sj.bmt.1703109
https://doi.org/10.1038/sj.bmt.1703109
Autor:
Richard S. Stein, Stephen J. Brandt, Madan Jagasia, John P. Greer, David S. Morgan, Steven N. Wolff, Stacey Goodman, Thomas L. McCurley, Edward R. Arrowsmith, John M. Flexner
Publikováno v:
Leukemia & Lymphoma. 42:913-922
Between 1991 and 1999, 67 patients with acute non-lymphocytic leukemia (ANLL) in complete remission received high dose cytarabine (HiDAC) 3 gm/m2 q12h x 12 doses followed by daunorubicin 45 mg/m2/day x 3 days as consolidation therapy. Five year actua
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::133558e3050a4b24742967fb87d7a44d
https://doi.org/10.3109/10428190109097710
https://doi.org/10.3109/10428190109097710
Autor:
Steven N. Wolff
Publikováno v:
Current Opinion in Organ Transplantation. 5:372-381
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::0ffb6d2756c81c264a8b84621623da01
https://doi.org/10.1097/00075200-200012000-00012
https://doi.org/10.1097/00075200-200012000-00012
Autor:
Terri Hagan, Patricia Price, Tonya R. Edens, Peter E. Morris, Timothy S. Blackwell, Brian W. Christman, John W. Christman, Steven N. Wolff, Stacey Goodman
Publikováno v:
Antioxidants & Redox Signaling. 2:93-102
Although in vitro data has linked reactive oxygen species (ROS) to activation of nuclear factor kappaB (NF-kappaB), little data exist regarding this relationship in human disease. We hypothesized that bone marrow transplantation (BMT) would impart a
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::030f0d90602e126a35e60755cedb2d84
https://doi.org/10.1089/ars.2000.2.1-93
https://doi.org/10.1089/ars.2000.2.1-93
Autor:
John P. Greer, Richard S. Stein, Stephen J. Brandt, William R. Macon, Stacey Goodman, Steven N. Wolff, David S. Morgan, Thomas L. McCurley
Publikováno v:
Bone Marrow Transplantation. 25:257-262
Between September 1986 and June 1998, 99 patients with relapsed or refractory IGL received intensified preparative therapy and underwent autologous transplantation at a single institution. Two intensified preparative regimens were used: cyclophospham
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::dae060a8ed8a3d8c0d7d11b61bd3e150
https://doi.org/10.1038/sj.bmt.1702132
https://doi.org/10.1038/sj.bmt.1702132
Autor:
Patrick J. Stiff, Alan F. List, J. A. Bianco, F. Andrews, R. Maziarz, Chatchada Karanes, S. Dahlberg, J. Jansen, B. Kirkhart, Mark R. Litzow, M. Schuster, Jack W. Singer, Steven N. Wolff, Jane L. Liesveld
Publikováno v:
Scopus-Elsevier
the purpose of the study was to evaluate the effect of lisofylline (lsf) on engraftment, regimen-related toxicities (rrt), and mortality in patients undergoing allogeneic bone marrow transplantation (bmt). we performed a multicenter, randomized place
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::a0df44201f311ac803fe114f34ad5c2b
https://doi.org/10.1038/sj.bmt.1702114
https://doi.org/10.1038/sj.bmt.1702114
Autor:
L. Pineiro, Stacy A. Goodman, Roger H. Herzig, Linda J. Goldsmith, John P. Greer, R Brown, Joseph P. Lynch, Brian J. Bolwell, Geoffrey P. Herzig, Don A. Stevens, Richard S. Stein, Steven N. Wolff, Robert H. Collins, Joseph W. Fay, Donald R. Fleming
Publikováno v:
Leukemia & Lymphoma. 35:91-98
To determine the long-term results of high-dose chemotherapy and stem cell support in relapsed or primary refractory Hodgkin disease patients. One hundred and thirty-one patients with relapsed or primary refractory Hodgkin's disease were treated with
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::ecdbd0c39ff4068d8d8c48b69ff4cc83
https://doi.org/10.3109/10428199909145708
https://doi.org/10.3109/10428199909145708